BACKGROUND: The purpose of this study was to examine the interactive effects of family history of alcoholism (FH+, FH-) and naltrexone dose (0, 50, 100 mg/day) on alcohol drinking. METHODS: Ninety-two, non-treatment-seeking alcohol-dependent participants received naltrexone daily for 6 days. On the 6th day, they participated in a laboratory paradigm involving exposure to a priming dose of alcohol followed by a 2-hour drinking period in which they made choices between consuming alcoholic drinks and receiving money. RESULTS: Total number of drinks consumed during the drinking period was significantly decreased by the 100-mg dose of naltrexone in FH+ drinkers. Secondary analyses in male drinkers (n = 70) indicated that 100 mg of naltrexone significantly decreased drinking in FH+ participants and increased drinking in FH- drinkers. CONCLUSIONS: These results suggest that family history of alcoholism might be a significant clinical predictor of response to naltrexone and that FH+ men are more likely to benefit from naltrexone therapy for alcohol drinking.
BACKGROUND: The purpose of this study was to examine the interactive effects of family history of alcoholism (FH+, FH-) and naltrexone dose (0, 50, 100 mg/day) on alcohol drinking. METHODS: Ninety-two, non-treatment-seeking alcohol-dependent participants received naltrexone daily for 6 days. On the 6th day, they participated in a laboratory paradigm involving exposure to a priming dose of alcohol followed by a 2-hour drinking period in which they made choices between consuming alcoholic drinks and receiving money. RESULTS: Total number of drinks consumed during the drinking period was significantly decreased by the 100-mg dose of naltrexone in FH+ drinkers. Secondary analyses in male drinkers (n = 70) indicated that 100 mg of naltrexone significantly decreased drinking in FH+ participants and increased drinking in FH- drinkers. CONCLUSIONS: These results suggest that family history of alcoholism might be a significant clinical predictor of response to naltrexone and that FH+ men are more likely to benefit from naltrexone therapy for alcohol drinking.
Authors: Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Meghan Morean; Julia Shi; Brian Pittman; John H Krystal Journal: Alcohol Clin Exp Res Date: 2015-02-09 Impact factor: 3.455
Authors: S Jamadar; E E DeVito; R E Jiantonio; S A Meda; M C Stevens; M N Potenza; J H Krystal; G D Pearlson Journal: Psychopharmacology (Berl) Date: 2012-02-04 Impact factor: 4.530
Authors: Erica N Grodin; Spencer Bujarski; Alexandra Venegas; Wave-Ananda Baskerville; Steven J Nieto; J David Jentsch; Lara A Ray Journal: Alcohol Alcohol Date: 2019-12-01 Impact factor: 2.826
Authors: Stephanie S O'Malley; Suchitra Krishnan-Sarin; Sherry A McKee; Robert F Leeman; Ned L Cooney; Boris Meandzija; Ran Wu; Robert W Makuch Journal: Int J Neuropsychopharmacol Date: 2008-09-17 Impact factor: 5.176
Authors: Krysten W Bold; Lisa M Fucito; William R Corbin; Kelly S DeMartini; Robert F Leeman; Henry R Kranzler; Stephanie S O'Malley Journal: Exp Clin Psychopharmacol Date: 2016-10 Impact factor: 3.157